Fermentation-based pharmaceutical ingredient (API) manufacturer specializing in immunosuppressants and oncology drugs.
Fermentation-based pharmaceutical ingredient (API) manufacturer specializing in immunosuppressants and oncology drugs.
Grows microbes in large fermentation tanks to produce active ingredients, such as the transplant-rejection drug tacrolimus, and sells them in bulk to generic drug makers, competing on yield, quality and regulatory approvals in each market. It listed on the stock market in 2023.
In one line: A niche fermentation-API maker, akin to a smaller Teva API arm.
Moat: narrow (process know-how, regulatory licence). Complex fermentation-based API manufacturing expertise and regulatory approvals create high entry barriers.
Headquarters: Ahmedabad, India · Founded: 1984 · Employees: 1,624
Size Concord Biotech (CONCORDBIO.NS) is an India Industrials company (Miscellaneous Commercial Services) with a market value of $1.26B, the 539th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹561.00 on 18 Nov 2026.
Performance Over six months the shares fell 1.9%, against -19.7% for the median peer and +3.8% for the India market (cap-weighted) — 7th highest of 21 in its peer set.
Growth Revenue grew 4.0% over the last twelve months (peer median +10.0%); the operating margin is 28.1% (peer median 9.6%).
Valuation It trades at 33.9× forward earnings against a peer median of 27.1× (8th most expensive of 17).
Price implies For today's price to make sense, revenue must grow about 44% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is +33 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 4.0 points below its cost of capital (19.2% WACC).
Next results Next results expected around 18 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹11.7B | ₹10.5B | ₹11.8B | ₹9.98B | ₹8.31B |
| Revenue growth | — | -11% | +18% | +20% | — |
| Gross profit | ₹4.96B | ₹4.17B | ₹5.54B | ₹4.72B | ₹3.71B |
| EBITDA | ₹4.04B | ₹3.71B | ₹4.96B | ₹4.19B | ₹3.33B |
| Net income | ₹2.82B | ₹2.61B | ₹3.72B | ₹3.08B | ₹2.40B |
| Free cash flow | n/a | ₹1.74B | ₹1.36B | ₹1.82B | ₹1.06B |
| Capital expenditure | n/a | ₹952M | ₹1.11B | ₹857M | ₹1.45B |
| Total debt | ₹17.5M | ₹23.2M | ₹29.7M | ₹97.4M | ₹315M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Concord Biotech CONCORDBIO.NS | $1.26B | -2% | +4% | 28% | 33.9× | 44.4% |
| Divi's Laboratories DIVISLAB.NS | $31.3B | +60% | +22% | 34% | 73.5× | 47.1% |
| Biocon BIOCON.NS | $6.31B | -15% | +6% | 8% | 61.3× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CONCORDBIO.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -12.7% | -2.3% | 6th lowest of 21 |
| 6-month return | -1.9% | -19.7% | 7th highest of 21 |
| Distance from 52-week high | -30.5% | -37.7% | 7th highest of 21 |
| Revenue growth (TTM) | +4.0% | +10.0% | 5th lowest of 21 |
| Operating margin | 28.1% | 9.6% | 2nd highest of 21 |
| Forward P/E | 33.9× | 27.1× | 8th most expensive of 17 |
| Growth the price implies (Req g, 7 yrs) | 44.4% | 12.6% | 2nd most demanding of 17 |
| Growth delivered (Del g) | +11.6% | +14.1% | 6th lowest of 16 |
| Hurdle (Req g minus delivered) | +32.8 pp | -1.5 pp | 3rd most demanding of 16 |
| ROIC minus cost of capital | -4.0 pp | -0.9 pp | 7th lowest of 21 |
| EV / EBITDA | 27.9× | 8.4× | most expensive of 9 |
| Net debt / EBITDA | -1.1× | 1.8× | 3rd least indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Concord Biotech CONCORDBIO.NS | India | $1.26B | -2% | +4% | 28% | 33.9× | 44.4% | +11.6% |
| Suzhou Recodeal Interconnect System 688800.SS | China | $1.26B | -68% | +5% | 9% | 31.0× | 22.7% | +38.9% |
| Shanghai MicroPort EP Medtech 688351.SS | China | $1.31B | -30% | +20% | 3% | 137.1× | 42.5% | +26.7% |
| TKC 9746.T | Japan | $1.31B | +22% | +5% | 20% | 19.1× | -10.1% | +5.7% |
| Siglent Technologies 688112.SS | China | $1.19B | -26% | +30% | 24% | 39.2× | 27.7% | +22.0% |
| Shanxi Huaxiang 603112.SS | China | $1.19B | -33% | +9% | 11% | 11.6× | 0.9% | +16.2% |
| Changchun Up Optotech 002338.SZ | China | $1.34B | -41% | +22% | 2% | 43.1× | n/a | n/a |
| China Security 600654.SS | China | $1.34B | -31% | -30% | -1% | n/a | 56.0% | +0.4% |
| China National Electric Apparatus Research Institute 688128.SS | China | $1.35B | -17% | +8% | 11% | 14.7× | 3.2% | +13.5% |
| Nittetsu Mining 1515.T | Japan | $1.17B | -3% | +18% | 8% | n/a | n/a | n/a |
| SBS 2384.T | Japan | $1.35B | +26% | +17% | 5% | 13.9× | -4.7% | +13.8% |
| CRA International CRAI | United States | $1.35B | +46% | +13% | 10% | 23.3× | 6.6% | +8.1% |
| PharmaBlock Sciences (Nanjing) 300725.SZ | China | $1.36B | +5% | +11% | 11% | 37.5× | 24.2% | +14.1% |
| Resolute Holdings Management RHLD | United States | $1.16B | +34% | +10% | 12% | n/a | 16.6% | n/a |
| Derichebourg DBG.PA | France | $1.37B | -18% | -3% | 5% | 8.8× | 6.7% | +6.3% |
| Jadard Technology 688252.SS | China | $1.14B | -22% | +6% | 12% | 22.3× | 12.0% | +31.3% |
| Clarivate CLVT | United States | $1.38B | -12% | -9% | 8% | 3.5× | 13.2% | +14.4% |
| Central Mine Planning & Design Institute CMPDI.NS | India | $1.38B | -22% | +10% | 33% | n/a | 4.5% | +18.7% |
| Shanghai Medicilon 688202.SS | China | $1.39B | +8% | +42% | -2% | 85.1× | n/a | n/a |
| Shenzhen Ampron Technology 301413.SZ | China | $1.40B | -28% | +11% | 2% | 387.2× | n/a | n/a |
| Offcn Education Technology 002607.SZ | China | $1.40B | -40% | -2% | 13% | 34.7× | 15.7% | -27.6% |